title: Pharmacokinetics of epirubicin in man. Non-influence of alpha interferon.
abstract: The influence of alpha interferon on the plasma pharmacokinetics of epirubicin has been studied in five patients with bronchial cancer. The pharmacokinetic studies of epirubicin (100 mg m-2) were performed prior to and immediately after a 3 wk period with daily natural alpha interferon treatment (6 x 10(6) IU i.m.). None of the patients had been treated with antracyclines or interferon prior to entering the present study. The plasma pharmacokinetics of epirubicin were most adequately described by a three compartment open model both prior to and after the interferon treatment. The interferon treatment had no influence on the pharmacokinetics of epirubicin (AUC, Cmax, terminal half life).
authors.affiliation: Karolinska Pharmacy, Stockholm, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Eksborg
authors.forename: K
authors.initials: K
authors.lastname: Mattson
mesh_terms: D000368:Aged; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015251:Epirubicin; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D013237:Stereoisomerism
chemical_list: D007370:Interferon Type I; D015251:Epirubicin; D004317:Doxorubicin